Sixth Pharmaceutical Company Joins the CardioHealth Alliance, Further Expanding Reach and Impact of Evidence-Based Prevention and Care
CardioHealth Alliance welcomed Novo Nordisk Inc.
DCRI HEAL Connections Team Assembles Naloxone Kits at Team Building Event
At least 100 of the 500 naloxone kits assembled by the DCRI’s HEAL Connections team members in March will likely be used to help reverse opioid overdoses and possibly save lives.
DCRI Releases 2022 Impact Report
At the DCRI, we’re bringing creative solutions to the world’s most vexing health problems.
Boehringer Ingelheim and Eli Lilly and Company Join CardioHealth Alliance
A consortium called the CardioHealth Alliance brings together a multi-disciplinary group of experts to improve the care and health of patients across cardiovascular, renal and metabolic diseases.
Laos, Malawi, Rwanda and Zambia Receive Oral Antiviral Treatments for High-Risk Patients Through COVID Treatment Quick Start Consortium
The COVID Treatment Quick Start Consortium announced today that the governments of Zambia, Laos, Malawi and Rwanda have received shipments of PAXLOVID™ (nirmatrelvir/ritonavir), Pfizer’s COVID-19 o
DCRI Highlights From ACC.23 Together With WCC
DCRI faculty and staff took part in more than 80 events at the 2023 American College of Cardiology Scientific Sessions (ACC.23), paired together with the World Congress of Cardiology (WCC).
Intervention Helps Clinicians Meet Guidelines for Prescribing Diabetes, Heart Drugs
Education and interdisciplinary care are keys to overcoming barriers that prevent patients from receiving proven therapies
Duke Clinical Research Institute and Protas partner to transform the quality, accessibility and affordability of randomized clinical trials for common health conditions
Duke Clinical Research Institute (DCRI), the world’s largest academic research organization, will collaborate with Protas, a not-for-profit clinical trials organization led by renowned Oxford Unive
‘Don’t Miss a Beat’: DCRI’s Greene joins Brigham and Women’s Vaduganathan in monthly cardiology research podcast
Duke Clinical Research Institute cardiovascular faculty member Stephen Greene, MD, joins Brigham and Women’s cardi
EMPA-KIDNEY Trial shows benefits for CKD in broad range of patients
A recent trial of empagliflozin expanded the understanding of how the drug can slow chronic kidney disease in a wide range of patients, lowering the risk of disease progression and death from cardi